10-K: Q/C Technologies Details Capital Stock Structure

Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) has filed a description of its capital stock, outlining authorized shares, common and preferred stock details, and the rights associated with each class.

Summary

• This filing details the capital stock structure of Q/C Technologies, Inc., including authorized shares, common stock rights, and various series of preferred stock.
• The company has authorized 300,000,000 shares, comprising 250,000,000 shares of Common Stock and 50,000,000 shares of preferred stock.
• Several series of preferred stock are designated, including Series C, D, E, F, F-1, G, H, and I, with specific conversion, dividend, and liquidation rights.
• Common stockholders have one vote per share, and director elections are by plurality vote.
• The company has not paid cash dividends on its Common Stock and does not intend to in the foreseeable future, aiming to retain earnings for operations.
• The filing also details anti-takeover provisions within the company's charter, bylaws, and Delaware law.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the complexity of the capital structure and the lack of immediate dividend prospects for common stockholders, although it provides necessary transparency on corporate structure.

Positives

• The company has a clear structure for its authorized capital stock, outlining common and preferred stock classes.
• Detailed descriptions of conversion, dividend, and liquidation rights for various preferred stock series provide transparency to investors.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol QCLS, providing liquidity and accessibility for investors.

Negatives

• The company has a complex capital structure with multiple series of preferred stock, which can lead to complex rights and potential dilution.
• The existence of preferred stock with potential voting or conversion rights that could adversely affect common stockholders is a concern.
• The company has not paid cash dividends and does not intend to in the foreseeable future, meaning investors must rely solely on stock appreciation for returns.

Risks

• The authorization of undesignated preferred stock allows the board to issue preferred stock with rights that could impede a change in control, potentially discouraging takeover offers.
• Anti-takeover provisions in the charter, bylaws, and Delaware law could deter unsolicited acquisition proposals and limit the ability of stockholders to effect changes in management or board composition.
• The potential for dilution exists if the company issues additional equity securities, including through the conversion of preferred stock or exercise of warrants.
• The company's ability to meet Nasdaq's continued listing requirements, such as minimum bid price and stockholders' equity, is a risk that could lead to delisting.
• The company's reliance on a licensing agreement with LightSolver Ltd. for its laser-based computing technology poses a risk if this agreement is terminated or if there are intellectual property disputes.

Future Outlook

The company intends to retain all earnings to finance operations and does not currently anticipate paying cash dividends on its Common Stock in the foreseeable future. Future dividend declarations will be at the board's discretion.

Industry Context

StockSavvy.ai notes that the detailed description of capital stock is a standard component of SEC filings, providing crucial information for investors regarding ownership structure and rights. The company's shift towards laser-based computing for blockchain and AI aligns with emerging technology trends, but the complexity of its preferred stock offerings and associated anti-dilution provisions are key considerations for potential investors.

Corporate Governance

Legal Proceedings

• The filing mentions a settled lawsuit filed by Raymond F. Akers, Jr. against the company for whistleblower retaliation, which was confidentially settled on April 29, 2025, with no material impact on the company's financial condition or results of operations.

Related Party Transactions

• The company entered into purchase agreements for Series G and Series H Preferred Stock with PharmaCyte Biotech, Inc., where Joshua Silverman, interim CEO of PharmaCyte, also serves as the Company's Executive Chairman.

Stakeholder Impact

• Common stockholders may experience dilution due to the potential issuance of additional equity securities and the complex rights associated with preferred stock.
• Preferred stockholders have specific rights regarding dividends, conversion, and liquidation, which are detailed in the filing.
• The company's strategy to retain earnings for operations means common stockholders must rely on capital appreciation for returns.

Key Dates

Keywords

Q/C Technologies, TNF Pharmaceuticals, Capital Stock, Common Stock, Preferred Stock, Series C Convertible Preferred Stock, Series D Convertible Preferred Stock, Series E Junior Participating Preferred Stock, Series F Convertible Preferred Stock, Series F-1 Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series I Convertible Preferred Stock, Nasdaq, SEC Filing, Corporate Governance, Shareholder Rights